Investigation Launched into Curanex Pharmaceuticals for Possible Securities Fraud Claims

Investigation of Curanex Pharmaceuticals Inc. for Potential Securities Fraud

Wolf Haldenstein Adler Freeman & Herz LLP has embarked on an investigation concerning potential claims of securities fraud involving shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX). This inquiry aims to determine if Curanex, alongside certain officers and directors, has participated in fraudulent activities or other illicit business conduct.

Curanex Pharmaceuticals Inc. operates as a developmental-stage pharmaceutical company concentrating on the discovery, development, and commercialization of botanical-based drugs targeting immune and inflammatory diseases. The firm conducted its Initial Public Offering (IPO) on August 26, 2025, during which it sold 3.75 million shares priced at $4.00 each, resulting in gross proceeds amounting to $15 million. The IPO was organized by the lead underwriter, Dominari Securities, which also exercised an overallotment of 562,500 shares.

Following the IPO, Curanex's stock experienced significant activity, with share prices climbing due to heightened trading volumes. The peak was reached on September 16, 2025, with shares closing at $9.16. However, the stock faced extreme volatility, leading to a halt on September 17, only to plummet to $1.51 by the day's end, amidst trading activity of 26 million shares. This rapid rise and fall of stock prices have raised red flags, prompting the investigation into potential misconduct.

Wolf Haldenstein has extensive experience in dealing with securities class actions and derivative litigation in both state and federal courts throughout the country. The firm has gained recognition for its expertise and reputation in shareholder litigation cases, having been appointed for major roles in complex, multi-district, and consolidated securities litigations. They are committed to ensuring that shareholders are informed of their rights and any implications surrounding this ongoing inquiry.

If you are a shareholder of Curanex Pharmaceuticals and have incurred financial losses, you are encouraged to reach out to Wolf Haldenstein for more information about your rights and interests. The firm can be reached by phone at (800) 575-0735 or (212) 545-4774, or you can email them at [email protected] It is crucial for affected individuals to discuss their concerns promptly, as the investigation unfolds.

For continuous updates and further details, shareholders can visit the firm's official website at www.whafh.com. Additionally, individuals are invited to fill out a contact form to initiate a discussion regarding their circumstances or to seek legal advice.

The ongoing developments in this case will undoubtedly be of interest to not only current shareholders of Curanex but also to potential investors watching the pharmaceutical sector closely. Stay tuned for more updates as this investigation progresses and further information emerges regarding the practices of Curanex Pharmaceuticals Inc.